izpis_h1_title_alt

Comparison of clinical, laboratory and immune characteristics of the monophasic and biphasic course of tick-borne encephalitis
ID Bogovič, Petra (Avtor), ID Lotrič-Furlan, Stanka (Avtor), ID Avšič-Županc, Tatjana (Avtor), ID Korva, Miša (Avtor), ID Kastrin, Andrej (Avtor), ID Lusa, Lara (Avtor), ID Strle, Klemen (Avtor), ID Strle, Franc (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (439,50 KB)
MD5: 1089A951694C78DBC6B2C4D021AF0499
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2076-2607/9/4/796 Povezava se odpre v novem oknu

Izvleček
The biphasic course of tick-borne encephalitis (TBE) is well described, but information on the monophasic course is limited. We assessed and compared the clinical presentation, laboratory findings, and immune responses in 705 adult TBE patients: 283 with monophasic and 422 with biphasic course. Patients with the monophasic course were significantly (p ≤ 0.002) older (57 vs. 50 years), more often vaccinated against TBE (7.4% vs. 0.9%), more often had comorbidities (52% vs. 37%), and were more often treated in the intensive care unit (12.4% vs. 5.2%). Multivariate logistic regression found strong association between the monophasic TBE course and previous TBE vaccination (OR = 18.45), presence of underlying illness (OR = 1.85), duration of neurologic involvement before cerebrospinal fluid (CSF) examination (OR = 1.39), and patients’ age (OR = 1.02). Furthermore, patients with monophasic TBE had higher CSF levels of immune mediators associated with innate and adaptive (Th1 and B-cell) immune responses, and they had more pronounced disruption of the blood–brain barrier. However, the long-term outcome 2–7 years after TBE was comparable. In summary, the monophasic course is a frequent and distinct presentation of TBE that is associated with more difficult disease course and higher levels of inflammatory mediators in CSF than the biphasic course; however, the long-term outcome is similar.

Jezik:Angleški jezik
Ključne besede:tick-borne encephalitis, monophasic course, biphasic course, long-term outcome, cerebrospinal fluid, cytokines, chemokines, innate immune responses, adaptive immune responses
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2021
Št. strani:12 str.
Številčenje:Vol. 9, iss. 4, art. 796
PID:20.500.12556/RUL-135544 Povezava se odpre v novem oknu
UDK:606.9
ISSN pri članku:2076-2607
DOI:10.3390/microorganisms9040796 Povezava se odpre v novem oknu
COBISS.SI-ID:59073539 Povezava se odpre v novem oknu
Datum objave v RUL:18.03.2022
Število ogledov:801
Število prenosov:114
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Microorganisms
Skrajšan naslov:Microorganisms
Založnik:MDPI AG
ISSN:2076-2607
COBISS.SI-ID:523277081 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:10.04.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:klopni encefalitis, cerebralna tekočina, citokini, imunski odziv

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0296
Naslov:Bolezni in povzročitelji, ki jih v Sloveniji prenašajo členonožci

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-1744
Naslov:Poglobljena analiza vplivov dejavnikov povzročitelja in gostitelja pri akutni in kronični lymski boreliozi

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-8195
Naslov:Dejavniki povzročitelja in gostitelja, ki vplivajo na klinične znake, težo in izid lymske borelioze

Financer:NIH - National Institutes of Health
Številka projekta:R21 AI144916

Financer:Drugi - Drug financer ali več financerjev
Program financ.:MGH-ECOR

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Global Lyme Alliance

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj